Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy

Clinical Cancer Research

Volumn 14, Issue 1, 2008, Pages 82-88

  Lee, Jeeyun ^a   Cheol, Keun Park ^a   Joon, Oh Park ^a   Lim, Taekyu ^a   Young, Suk Park ^a   Ho, Yeong Lim ^a   Lee, Inkyoung ^a   Tae, Sung Sohn ^a   Jae, Hyung Noh ^a   Jin, Seok Heo ^a   Kim, Sung ^a   Do, Hoon Lim ^a   Kim, Kyoung Mee ^a   Won, Ki Kang ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTOR E2F1;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIVITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIVITY; STOMACH ADENOCARCINOMA; TISSUE MICROARRAY;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DISEASE-FREE SURVIVAL; E2F1 TRANSCRIPTION FACTOR; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; PROGNOSIS; RADIOTHERAPY, ADJUVANT; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; THYMIDYLATE SYNTHASE; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 40949165837     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0612     Document Type: Article

References (32)

1. Cunningham D, Jost LM, Purkalne G, Oliveira J. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of gastric cancer. Ann Oncol 2005;16 Suppl 1:i22-3.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. Inoue M, Tsugane S. Epidemiology of gastric cancer in Japan. Postgrad Med J 2005;81:419-24.
4. Bae JM WY, Jung KW, Park JG. Annual report of the Korea Central Cancer Registry Program 2000: based on registered data from 131 hospitals. Cancer Res Treat 2002;34:77-83.
5. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30.
6. 2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005;63:1279-85.
7. Bell LA, Ryan KM. Life and death decisions by E2F-1. Cell Death Differ 2004;11:137-42.
8. LaThangue NB. The yin and yang of E2F-1: balancing life and death. Nat Cell Biol 2003;5:587-9.
9. 53- deficient mice. Nat Cell Biol 2003;5:655-60.
10. Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson NJ. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 1996;85:537-48.
11. Nguyen KH, Hachem P, Khor LY, et al. Adenoviral-E2F-1 radiosensitizes p53wild-type and p53 null human prostate cancer cells. Int J Radiat Oncol Biol Phys 2005;63:238-46.
12. Russo AJ, Magro PG, Hu Z, et al. E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents. Cancer Res 2006;66:7253-60.
13. Banerjee D, Schnieders B, Fu JZ, Adhikari D, Zhao SC, Bertino JR. Role of E2F-1 in chemosensitivity. Cancer Res 1998;58:4292-6.
14. 1 cyclin-dependent kinase activity. Genes Dev 1995;9:2873-87.
15. Wu L, Timmers C, Maiti B, et al. The E2F-1-3 transcription factors are essential for cellular proliferation. Nature 2001;414:457-62.
16. Belvedere O, Puglisi F, Di Loreto C, et al. Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer. Ann Oncol 2004;15:55-8.
17. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004;22:529-36.
18. Johnston PG, Lenz HJ, Leichman CG, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995;55:1407-12.
19. Boku N, Chin K, Hosokawa K, et al. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res 1998;4:1469-74.
20. Lenz HJ, Leichman CG, Danenberg KD, et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996;14:176-82.
21. Yeh KH, Shun CT, Chen CL, et al. High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil - based systemic chemotherapy. Cancer 1998;82:1626-31.
22. Choi J, Lim H, Nam DK, et al. Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer 2001;84:186-92.
23. Meng RD, Phillips P, El-Deiry WS. p53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of Adriamycin. Int J Oncol 1999;14:5-14.
24. Dong YB, Yang HL, Elliott MJ, McMasters KM. Adenovirus-mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II inhibitors. Cancer Res 2002;62:1776-83.
25. Elliott MJ, Farmer MR, Atienza C, Jr., et al. E2F-1 gene therapy induces apoptosis and increases chemosensitivity in human pancreatic carcinoma cells. Tumour Biol 2002;23:76-86.
26. Pruschy M, Wirbelauer C, Glanzmann C, Bodis S, Krek W. E2F-1 has properties of a radiosensitizer and its regulation by cyclin A kinase is required for cell survival of fibrosarcoma cells lacking p53. Cell Growth Differ 1999;10:141-6.
27. Nip J, Strom DK, Fee BE, Zambetti G, Cleveland JL, Hiebert SW. E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis. Mol Cell Biol 1997;17:1049-56.
28. Suzuki T, Yasui W, Yokozaki H, Naka K, Ishikawa T, Tahara E. Expression of the E2F family in human gastrointestinal carcinomas. Int J Cancer 1999;81:535-8.
29. Tahara M, Ochiai A, Fujimoto J, et al. Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil. Oncol Rep 2004;11:9-15.
30. 1/S- regulatory genes. Mol Cell Biol 1995;15:4215-24.
31. Kasahara M, Takahashi Y, Nagata T, et al. Thymidylate synthase expression correlates closely with E2F-1 expression in colon cancer. Clin Cancer Res 2000;6:2707-11.
32. Cho MY YS, Eom M, Zhang SP, Kim HS, Lee JI, Kim DS. A high thymidylate synthase expression is related to better outcome for advanced gastric cancer patients treated with 5-FU chemotherapy after curative resection. Korean J Pathol 2006;40:128-36.